Aquestive Therapeutics, Inc. Class Action Lawsuit - AQST
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Aquestive class action lawsuit seeks to represent purchasers or acquirers of Aquestive Therapeutics, Inc. (NASDAQ: AQST) securities between June 16, 2025 and January 8, 2026, inclusive (the “Class Period”). Captioned Modica v. Aquestive Therapeutics, Inc., No. 26-cv-02317 (D.N.J.), the Aquestive class action lawsuit charges Aquestive and Aquestive’s Chief Executive Officer with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Aquestive class action lawsuit, please provide your information in the form on this page. You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: Aquestive operates as a pharmaceutical company.
The Aquestive class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Aquestive created the false impression that Aquestive was on track to receive approval for Aquestive’s New Drug Application (“NDA”) for Anaphylm by the January 31, 2026 Prescription Drug User Fee Act (“PDUFA”) date; (ii) the U.S. Food and Drug Administration (“FDA”) identified deficiencies with Aquestive’s NDA for Anaphylm precluding labeling discussions and post-marketing commitments; and (iii) in order for the FDA to grant approval for any NDA, any deficiencies must be remedied, therefore the launch of Anaphylm was delayed, indicating that Aquestive failed to obtain approval for Anaphylm by the PDUFA date.
The Aquestive class action lawsuit alleges that on January 9, 2026, Aquestive disclosed that it was in receipt of an FDA letter that “identified deficiencies in the [Anaphylm] NDA that preclude discussion of labeling and post-marketing commitments at this time.” On this news, the price of Aquestive stock fell more than 37%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Aquestive securities during the Class Period to seek appointment as lead plaintiff in the Aquestive class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Aquestive investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Aquestive shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Aquestive class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.